BACKGROUND: The lymphatic system is a major route for cancer cell dissemination, and a potential target for antitumor therapy. Despite ongoing interest in this area of research, the real-time behavior of cancer cells trafficking in the lymphatic system is poorly understood due to lack of appropriate tools to image this process. MATERIALS AND METHODS: We have used monoclonal-antibody and fluorescence technology to color-code lymphatic vessels and the cancer cells inside them in a living animal. Monoclonal anti-mouse LYVE-1 antibody was conjugated to a green fluorophore and delivered to the lymphatic system of a nude mouse, allowing imaging of mouse lymphatics. Tumor cells engineered to express red fluorescent protein were then imaged traveling within the labeled lymphatics in real time. RESULTS: AlexaFluor-labeled monoclonal anti-mouse LYVE-1 created a durable signal with clear delineation of lymphatic architecture. The duration of fluorescent signal after conjugated LYVE-1 delivery was far superior to that of fluorescein isothiocyanate-dextran or control fluorophore-conjugated IgG. Tumor cells engineered to express red fluorescent protein delivered to the inguinal lymph node enabled real-time tracking of tumor cell movement within the green fluorescent-labeled lymphatic vessels. CONCLUSIONS: This technology offers a powerful tool for the in vivo study of real-time trafficking of tumor cells within lymphatic vessels, for the deposition of the tumor cells in lymph nodes, as well as for screening of potential antitumor lymphatic therapies.
BACKGROUND: The lymphatic system is a major route for cancer cell dissemination, and a potential target for antitumor therapy. Despite ongoing interest in this area of research, the real-time behavior of cancer cells trafficking in the lymphatic system is poorly understood due to lack of appropriate tools to image this process. MATERIALS AND METHODS: We have used monoclonal-antibody and fluorescence technology to color-code lymphatic vessels and the cancer cells inside them in a living animal. Monoclonal anti-mouseLYVE-1 antibody was conjugated to a green fluorophore and delivered to the lymphatic system of a nude mouse, allowing imaging of mouse lymphatics. Tumor cells engineered to express red fluorescent protein were then imaged traveling within the labeled lymphatics in real time. RESULTS:AlexaFluor-labeled monoclonal anti-mouseLYVE-1 created a durable signal with clear delineation of lymphatic architecture. The duration of fluorescent signal after conjugated LYVE-1 delivery was far superior to that of fluorescein isothiocyanate-dextran or control fluorophore-conjugated IgG. Tumor cells engineered to express red fluorescent protein delivered to the inguinal lymph node enabled real-time tracking of tumor cell movement within the green fluorescent-labeled lymphatic vessels. CONCLUSIONS: This technology offers a powerful tool for the in vivo study of real-time trafficking of tumor cells within lymphatic vessels, for the deposition of the tumor cells in lymph nodes, as well as for screening of potential antitumor lymphatic therapies.
Authors: Laura Rubbia-Brandt; Benoit Terris; Emile Giostra; Bertrand Dousset; Philippe Morel; Michael S Pepper Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain Journal: Science Date: 2002-04-25 Impact factor: 47.728
Authors: David M Berman; Sunil S Karhadkar; Andrew R Hallahan; Joel I Pritchard; Charles G Eberhart; D Neil Watkins; James K Chen; Michael K Cooper; Jussi Taipale; James M Olson; Philip A Beachy Journal: Science Date: 2002-08-30 Impact factor: 47.728
Authors: David M Berman; Sunil S Karhadkar; Anirban Maitra; Rocio Montes De Oca; Meg R Gerstenblith; Kimberly Briggs; Antony R Parker; Yutaka Shimada; James R Eshleman; D Neil Watkins; Philip A Beachy Journal: Nature Date: 2003-09-14 Impact factor: 49.962
Authors: Laureen M Sena; Steven J Fishman; Kathy J Jenkins; Heng Xu; Martin W Brechbiel; Celeste A S Regino; Nobuyuki Kosaka; Marcelino Bernardo; Peter L Choyke; Hisataka Kobayashi Journal: Nanomedicine (Lond) Date: 2010-10 Impact factor: 5.307
Authors: Narges K Tafreshi; Marilyn M Bui; Kellsey Bishop; Mark C Lloyd; Steven A Enkemann; Alexis S Lopez; Dominique Abrahams; Bradford W Carter; Josef Vagner; Stephen R Grobmyer; Stephen R Gobmyer; Robert J Gillies; David L Morse Journal: Clin Cancer Res Date: 2011-10-20 Impact factor: 12.531
Authors: Susan J Doh; Michael Yamakawa; Samuel M Santosa; Mario Montana; Kai Guo; Joseph R Sauer; Nicholas Curran; Kyu-Yeon Han; Charles Yu; Masatsugu Ema; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar Journal: Angiogenesis Date: 2018-07-03 Impact factor: 9.596
Authors: Hop S Tran Cao; Michele McElroy; Sharmeela Kaushal; Robert M Hoffman; Michael Bouvet Journal: Adv Drug Deliv Rev Date: 2011-06-28 Impact factor: 15.470